Nexgen Rx Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 8.86%
- Profit Growth 6.33%
- Ebitda 15.29%
- Net Worth 18.74%
- Total Assets 2.91%
About Nexgen Rx Lifesciences
Nexgen Rx Lifesciences Private Limited (NRLPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 September 2008 and has a history of 16 years and five months. Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Kumar, Rakesh Sundar, Manoj Chand, and One other member serve as directors at the Company.
Company Details
-
Location
Ghaziabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85100UP2008PTC035981
-
Company No.
035981
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Sep 2008
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Nexgen Rx Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Kumar
|
Director | 08-Sep-2008 | Current |
|
Rakesh Sundar
|
Additional Director | 08-Sep-2008 | Current |
|
Manoj Chand
|
Director | 08-Sep-2008 | Current |
|
Mohammad Hasan
|
Director | 08-Sep-2008 | Current |
Financial Performance of Nexgen Rx Lifesciences.
Nexgen Rx Lifesciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.86% increase. The company also saw a slight improvement in profitability, with a 6.33% increase in profit. The company's net worth Soared by an impressive increase of 18.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexgen Rx Lifesciences?
Unlock access to Nexgen Rx Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Nexgenrx Pharmaceuticals Private LimitedMohammad Hasan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nexgen Rx Lifesciences?
Nexgen Rx Lifesciences has a workforce of 166 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexgen Rx Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexgen Rx Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.